VISTENDO INC

Arcadia, CA · Medtech · Private

Portable handheld oculomotor and autonomic nervous system measurement device with ML-based TBI severity assessment software

vistendo.com →
Grants
$1.6M
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
$1.9M
3 awards · Defense
#226 of 4531 in medtech
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal contractDepartment of Defense · Medical Research And Development Purchase Order Dha SBIR Ph I Proposal No. H192-003-0027 Titled Portable Oculomotor And Multisensing Assessment System (pomas.$249,960
Federal contractDepartment of Defense · Medical Research And Development Dha SBIR Phase II Proposal No. H2-0609 Titled Portable Oculomotor And Multi-sensing Assessment System (pomas).$1,649,979
Federal contractDepartment of Defense · Portable Early Impairment Screening Device$49,963
Federal grantDepartment of Defense · Phase II · Portable Oculomotor and Multi-sensing Assessment System (POMAS)$1,649,979
Federal grant · SBIR/STTRFederal contract · USAspending

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
223TransMedics$2.0M$155M
224Karius$2.0M—
225CSA Medical, Inc.$2.0M$157M
226VISTENDO INC$1.9M—
227PURIOLABS, LLC$1.9M—
228QUANTUM DIAMOND TECHNOLOGIES INC$1.9M—
229INNOVEGA, INC.$1.9M$4.1M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.